Illumina has appointed Caroline Dorsa to its board of directors and to the board's audit committee. She joins Illumina from the Public Service Enterprise Group where she served as executive VP and CFO. Dorsa also serves as director of Biogen and Intellia Therapeutics, and as a trustee of Goldman Sachs MLP Income Opportunities Fund and Goldman Sachs MLP and Energy Renaissance Fund.
David Memel, Frank Fee
Metabolon has appointed David Memel as chief medical officer and Frank Fee as CFO. Memel joins Metabolon from Klaipeda Health where he served as managing director. He has also held a variety of commercial, medical, scientific, informatics, and technology leadership positions at Boehringer Ingelheim Pharmaceuticals, Aetna, Roche Diagnostics, Roche Pharmaceuticals, and PeaceHealth. Fee has been with Metabolon since 2011, where he most recently served as senior VP of finance. Before joining Metabolon, he worked in the life sciences practice of Ernst & Young.
Michael Murphy, Sandra Foster, Michael Reinemann
Akonni Biosystems has appointed Michael Murphy as VP of regulatory affairs, Sandra Foster as director of quality assurance, and Michael Reinemann as director of business development. Murphy joins Akonni from Conatus Consulting, a regulatory consulting practice, where he served as president for seven years. He has also held executive management positions at ParagonDx, PPGx, Clingenix, and Gentris. Foster joins Akonni from her own private consulting company, Triangle GxP Solutions. She has also spent 12 years in various clinical-phase biotechnology companies. Reinemann joins Akonni from Qiagen, where he held various commercial operations roles, including regional marketing manager of North America and senior global product manager.
For more recent items on executive appointments and promotions in the omics and molecular diagnostics industries, please see the People in the News page on our website.